Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBIG for cure: Hepatitis B immunoglobulins to induce HBsAg clearance in chronic hepatitis B
2024-513792-41-00Phase 2Completed
- Sponsor
- Medizinische Hochschule Hannover
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of hepatitis B immune globulin and HepBQuin in Chronic Hepatitis B (CHB) (2 cohorts), sponsored by Medizinische Hochschule Hannover. Primary endpoint: HBsAg negativity at week 12 of antiviral therapy. Started Nov 2024; status: completed.
02
Drugs
hepatitis B immune globulinHepBQuin
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2024-513792-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513792-41-00.